Macitentan and Tadalafil Combination Therapy in Incident and Prevalent Pulmonary Arterial Hypertension: Real-World Evidence from the OPUS/OrPHeUS Studies

Overview

Journal Adv Ther

Date 2024 Sep 24

PMID 39316293

Authors

Kelly M Chin

Richard Channick

Nick H Kim

Gwen MacDonald

Rose Ong

Nicolas Martin

Assunta Senatore

Vallerie V McLaughlin

Affiliations

Soon will be listed here.

Abstract

Introduction: Historically, patients recently (≤ 6 months) diagnosed with pulmonary arterial hypertension (PAH; incident) have had poorer survival than those with a longer (> 6 months) time from PAH diagnosis (prevalent). Despite guideline recommendations for initial combination therapy for most patients with PAH, many are initiated and maintained on monotherapy. Real-world evidence to evaluate the benefit of early combination treatment in newly-diagnosed patients is lacking.

Methods: Patients with PAH initiating combination therapy with the endothelin receptor antagonist macitentan and the phosphodiesterase-5 inhibitor tadalafil (M+T) were identified from the combined dataset of the US, multicenter OPUS (prospective, observational drug registry; NCT02126943) and OrPHeUS (retrospective, medical chart review; NCT03197688) studies (2013-2020). Descriptive analyses were performed for the incident and prevalent cohorts, as well as the subcohort of incident patients who received M+T as first-line combination therapy (incident initial combination).

Results: In OPUS/OrPHeUS, 1336 patients with PAH received M+T during the observation period. For the incident [n = 453 (33.9%)], incident initial combination [n = 272 (20.4%)], and prevalent [n = 837 (62.6%)] cohorts: median (Q1, Q3) M+T exposure was 14.2 (4.2, 27.5), 12.2 (3.2, 25.5), and 14.7 (4.5, 28.0) months. 12-month Kaplan-Meier estimates (95% confidence limits) for survival were 91.2% (87.7, 93.7), 88.5% (83.2, 92.2), and 92.9% (90.6, 94.6), for patients free from hospitalization were 59.4% (54.1, 64.4), 56.3% (49.1, 62.9), and 62.3% (58.5, 65.9), and for patients persisting on combination therapy were 68.6% (63.9, 72.8), 65.0% (58.8, 70.6) and 66.9% (63.5, 70.0). Adverse events (OPUS only) were reported in 77.8%, 80.2%, and 80.3% of patients, respectively, with no unexpected adverse events observed.

Conclusions: Despite a historically worse prognosis, incident patients receiving M+T, including as initial combination therapy, had similar survival and hospitalization as prevalent patients. Safety profiles were similar across cohorts. Together, these data support the use of early combination therapy with macitentan and tadalafil.

References

Humbert M, Sitbon O, Yaici A, Montani D, OCallaghan D, Jais X . Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010; 36(3):549-55. DOI: 10.1183/09031936.00057010. View

Farber H, Miller D, Poms A, Badesch D, Frost A, Muros-Le Rouzic E . Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015; 148(4):1043-54. DOI: 10.1378/chest.15-0300. View

Miller D, Gomberg-Maitland M, Humbert M . Survivor bias and risk assessment. Eur Respir J. 2012; 40(3):530-2. DOI: 10.1183/09031936.00094112. View

Chang K, Duval S, Badesch D, Bull T, Chakinala M, De Marco T . Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. J Am Heart Assoc. 2022; 11(9):e024969. PMC: 9238604. DOI: 10.1161/JAHA.121.024969. View

Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S . A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2017; 39(47):4175-4181. DOI: 10.1093/eurheartj/ehx257. View

Lajoie A, Lauziere G, Lega J, Lacasse Y, Martin S, Simard S . Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016; 4(4):291-305. DOI: 10.1016/S2213-2600(16)00027-8. View

Galie N, Barbera J, Frost A, Ghofrani H, Hoeper M, McLaughlin V . Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(9):834-44. DOI: 10.1056/NEJMoa1413687. View

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Respir J. 2015; 46(4):903-75. DOI: 10.1183/13993003.01032-2015. View

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

Humbert M, Kovacs G, Hoeper M, Badagliacca R, Berger R, Brida M . 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43(38):3618-3731. DOI: 10.1093/eurheartj/ehac237. View

10.

Humbert M, Kovacs G, Hoeper M, Badagliacca R, Berger R, Brida M . 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2022; 61(1). DOI: 10.1183/13993003.00879-2022. View

11.

Boucly A, Savale L, Jais X, Bauer F, Bergot E, Bertoletti L . Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2021; 204(7):842-854. DOI: 10.1164/rccm.202009-3698OC. View

11.

McLaughlin V, Channick R, Kim N, Frantz R, McConnell J, Melendres-Groves L . Safety of macitentan for the treatment of pulmonary hypertension: Real-world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS). Pulm Circ. 2022; 12(4):e12150. PMC: 9661363. DOI: 10.1002/pul2.12150. View

12.

Hoeper M, Pausch C, Grunig E, Staehler G, Huscher D, Pittrow D . Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. Eur Respir J. 2021; 59(6). PMC: 9160392. DOI: 10.1183/13993003.02024-2021. View

13.

Pocock S, Clayton T, Altman D . Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002; 359(9318):1686-9. DOI: 10.1016/S0140-6736(02)08594-X. View

14.

Simonneau G, Channick R, Delcroix M, Galie N, Ghofrani H, Jansa P . Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J. 2015; 46(6):1711-20. PMC: 4664609. DOI: 10.1183/13993003.00364-2015. View

15.

Muller A, Escribano-Subias P, Fernandes C, Fontana M, Lange T, Soderberg S . Real-World Management of Patients with Pulmonary Arterial Hypertension: Insights from EXPOSURE. Adv Ther. 2024; 41(3):1103-1119. PMC: 10879368. DOI: 10.1007/s12325-023-02730-8. View

16.

Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V . Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122(2):156-63. DOI: 10.1161/CIRCULATIONAHA.109.911818. View

17.

Ogbomo A, Tsang Y, Mallampati R, Panjabi S . The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States. J Manag Care Spec Pharm. 2022; 28(6):608-616. PMC: 10372985. DOI: 10.18553/jmcp.2022.28.6.608. View

18.

Tremblay E, Gosselin C, Mai V, Lajoie A, Kilo R, Weatherald J . Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Circulation. 2022; 146(8):597-612. DOI: 10.1161/CIRCULATIONAHA.121.058635. View